Introduction
============

Breast cancer, a heterogeneous group of tumors, is the most commonly diagnosed cancer in women globally. In spite of improvements in early diagnosis and development of several targeted therapeutic methods, breast cancer-related morbidity still remains high. The existing therapeutic approaches are associated with high toxicity, low efficacy, therapeutic resistance and therapy-related morbidity. Recent studies have reported that the natural products owing to their cancer preventive potential will pay a way for more effective, non-endocrine, nontoxic therapeutic approaches for anticancer therapies. Historically, phytomolecules have played a key role in the discovery and development of novel anticancer agents.[@b1-dddt-11-1859],[@b2-dddt-11-1859] *Withania somnifera* (commonly known as ashwagandha or Indian winter cherry) is one such medicinal plant, whose all parts are used as ayurvedic remedies for healing various diseases, including inflammation, arthritis, asthma and hypertension.[@b3-dddt-11-1859]--[@b5-dddt-11-1859] The root extract of *W. somnifera* is known as withanolide, which is composed of 14 bioactive compounds.[@b6-dddt-11-1859],[@b7-dddt-11-1859] Preclinical experimental data indicates that *W. somnifera* leaf and root extracts have anticancer potential.[@b8-dddt-11-1859],[@b9-dddt-11-1859] For example, chemically induced tumorigenesis in the stomach and skin of mice was inhibited significantly following administration of *W. somnifera* root.[@b9-dddt-11-1859] Although no controlled clinical trials of ashwagandha have been reported for any indication, it appears to have a relatively low toxicity profile based on a single human study[@b10-dddt-11-1859] and toxicological studies in mice.[@b11-dddt-11-1859] In ayurvedic medicine, ashwagandha has also been claimed as an effective agent against arthritis, anxiety, insomnia and stress.[@b12-dddt-11-1859] *W. somnifera* is currently regulated in the US and Europe as a dietary supplement. The first withanolide to be characterized was withaferin A (WFA), isolated in 1965,[@b13-dddt-11-1859] with its cytotoxic activities being the focus of interest.[@b14-dddt-11-1859],[@b15-dddt-11-1859] The noncytotoxic, anti-inflammatory[@b16-dddt-11-1859] and immunomodulatory mechanisms[@b17-dddt-11-1859] of WFA have however thus far remained rather than poorly considered.

WFA, an important lactone of the withanolide class of phytomolecules, is a highly oxygenated steroidal prototype found in *W. somnifera* and its related Solanacea species, and exhibits potential anticancer activities.[@b18-dddt-11-1859] It has been reported to have shown decreases in mammary tumors and pulmonary metastasis in an MMTV-neu transgenic model and is associated with increased apoptosis.[@b19-dddt-11-1859] WFA-induced apoptosis involves the production of reactive oxygen species[@b20-dddt-11-1859] and induction of FOXO3a and Bim,[@b21-dddt-11-1859] while WFA effectively inhibits oncogenic transcription factors such as STAT3,[@b22-dddt-11-1859] resulting in growth inhibition. It has been reported that WFA promotes Notch signaling, plays an oncogenic role and is also often hyperactive in breast cancer cells.[@b23-dddt-11-1859] Herein, we report the development of a quantitative structure activity relationship (QSAR) model for the antiproliferative activity of withanolide analogs against human breast (SK-Br-3 and MCF7/BUS) cancer cell lines. Moreover, druggability of the compounds was evaluated using Lipinski's "rule of five" and a series of absorption, distribution, metabolism, excretion and toxicity (ADMET) properties. Molecular docking simulations of these compounds against β-tubulin were also conducted to characterize their binding affinity and interactions.

Materials and methods
=====================

Molecular modeling
------------------

Molecular modeling studies of withanolide analogs were carried out using Sybyl-X 2.1 (Tripos International, St Louis, MO, USA). The biological activity of all the withanolide analogs measured as inhibitory concentration (GI~50~) was converted to negative logarithmic concentration in moles (pGI~50~). Drawing of structures and geometry optimization was performed using ChemBioOffice Suite Ultra v12.0 (2012; Cambridge Soft Corp., Cambridge, UK).[@b24-dddt-11-1859],[@b25-dddt-11-1859] The Surflex-Dock module in Sybyl was used to construct the binding orientation of withanolide analogs.[@b26-dddt-11-1859],[@b27-dddt-11-1859]

QSAR model development
----------------------

A QSAR model was developed to screen potential leads against human breast cancer cell lines SK-Br-3 and MCF7/BUS within a training set ([Tables S1](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf) and [S2](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)).[@b28-dddt-11-1859] A total of 52 physicochemical descriptors were calculated for each compound using Scigress Explorer v.7.7.0.47 (Fujitsu Ltd., Poland; [Tables S3](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)). The dataset division into training and test was based on structural/pharmacophore or chemical class similarity in order to include only diverse compounds. Similarly, to select the best subset of physicochemical properties, highly correlated chemical descriptors were excluded through covariance analysis using a correlation matrix ([Tables S4](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf) and [S5](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)). Finally, a robust QSAR model equation was derived by using multiple linear regression; irrelevant chemical descriptors were removed through a forward stepwise approach leading to a selection of 4 out of 52 descriptors in the final QSAR regression equation. The resulting QSAR model equation showed high regression coefficients (*r*^2^) of 0.93 and 0.91 with activity data from the SK-Br-3 and MCF7/BUS cell lines, respectively. The developed QSAR model was validated by predicting the experimental activity of compounds in a test set. Furthermore, the robustness of the developed models was accessed by cross-validation regression coefficient (rCV^2^) using leave-one-out, test set prediction and randomization methods.[@b29-dddt-11-1859]--[@b31-dddt-11-1859]

Molecular docking
-----------------

Molecular docking simulations were performed to predict the bioactive conformations and explore the binding interactions of withanolide analogs using the Surflex-Dock module of Sybyl X 2.1. The crystal structure of β-tubulin (Protein Data Bank \[PDB\] code 4IHJ)[@b32-dddt-11-1859] was used as the potential anticancer drug target, with the dataset of compounds as ligands. The Surflex-Dock scoring function was used to assess the strength of the ligand--protein interactions. This scoring function includes energy terms to account for hydrophobicity, polarity, repulsiveness, entropy and solvation. Docking simulations were conducted allowing ligand flexibility but maintaining the protein structure rigid, while all docking parameters were set to default values.

QSAR model validation
---------------------

A reliable and predictive QSAR model should 1) be statistically significant and robust; 2) provide accurate predictions for external datasets not used during the model development and 3) have its application boundaries defined.

### Cross-validation techniques

To explore the reliability of QSAR models, a leave-one-out procedure was performed. The outcome from the cross- validation procedure was cross-validation regression coefficient (rCV^2^), which was used as a criterion of both robustness and predictive ability of the model. It was calculated using the following equation: $$\text{rCV}^{2} = 1 - \frac{\sum\left( {Y_{\text{obs}} - Y_{\text{pred}}} \right)^{2}}{\sum\left( {Y_{\text{obs}} - \overline{Y}} \right)^{2}}$$

In the above equation, $\overline{Y}$ means the average activity value of the training dataset, while Y~obs~ and Y~pred~ represent the observed and predicted activity values. A high rCV^2^ (\>0.5) suggests a reasonably robust model.

### Y-randomization test

In this technique, the dependent variable (biological activity) is randomly shuffled, and a new QSAR model is developed using the original independent variable. The new QSAR models (after several trials) are expected to have low *r*^2^ and rCV^2^ values; if the reverse happens, then an acceptable QSAR model cannot be obtained for the specific modeling method and data. These techniques ensure the robustness of a QSAR model.

### Estimation of the predictive ability of a QSAR model

To ensure the high predictive power of a QSAR model, it should be estimated by an external test set of compounds that are not used in building of the QSAR model. The external validation or predictive capacity of the derived model was judged by predictive $r^{2}(r_{\text{pred}}^{2})$ as shown in the following equation: $$r_{\text{pred}}^{2} = 1 - \frac{\sum\left( {Y_{\text{pred}(\text{test})} - Y_{(\text{test})}} \right)^{2}}{\sum\left( {Y_{(\text{test})} - Y_{(\text{training})}} \right)^{2}}$$where Y~pred~ (test) and Y~(test)~ indicate the predicted and observed activity values, respectively, for test set compounds and ${\overline{Y}}_{(\text{training})}$ indicates the average bioactivity of compound in the training set. An acceptable predictive power of a QSAR model $(r_{\text{pred}}^{2})$ should be \>0.6 for the test set molecules.[@b33-dddt-11-1859]--[@b35-dddt-11-1859]

### Defining the model -- applicability domain (AD)

AD was calculated by the using 23 and 24 inhibitors of MCF7BUS and Sk-Br-3 cell lines used in bioassay model building. It was designed in the form of range values of Lipinski's parameters, connectivity index (order 0, standard), dipole vector X (debye) and molar refractivity shape index (basic kappa, order 2) in [Figure 1](#f1-dddt-11-1859){ref-type="fig"} and the connectivity index (order 0, standard), dipole vector X (debye) and shape index (basic kappa, order 2) inhibition in [Figure 2](#f2-dddt-11-1859){ref-type="fig"}. The input parameters for queried compounds were screened through AD decided by the training set.

Prediction of pharmacokinetic (PK) parameters
---------------------------------------------

It would be advantageous in the process of drug discovery, if the ADMET properties of drug molecules were predicted earlier. This information helps the chemist to assess the PK profile of molecules. The PK properties depend on chemical descriptors of drugs, which determine their ADMET. The PK parameters were calculated by QikProp v3.2[@b36-dddt-11-1859] module of Schrödinger Suite 2011. A number of mathematical predictive ADMET models for different PK parameters were available, namely, aqueous solubility, apparent Caco-2 and MDCK permeability, log *K*~p~ for skin permeability, blood--brain barrier (BBB; log BB), the volume of distribution and plasma protein binding (shown as log *K*~hsa~ for serum protein binding), which were used to quantitatively predict the ADMET properties of the withanolide analogs. Similarly, the drug-likeness (DL) parameters, such as molecular weight (MW) of ≤500 Da, a logP value of ≤5, hydrogen bond donor ≤5 and hydrogen bond acceptor site (N and O atoms) ≤10, and Veber's parameters, namely, topological polar surface area (TPSA) (≤140 Å[@b2-dddt-11-1859]), which assess the passive molecular transport through membranes and number of rotatable bonds (≤10), used for flexibility measurement were calculated.[@b35-dddt-11-1859],[@b37-dddt-11-1859]--[@b39-dddt-11-1859]

Results and discussion
======================

QSAR model for antiproliferative activity against the SK-Br-3 cell line
-----------------------------------------------------------------------

All the withanolide analogs were evaluated for their predictivity through the developed QSAR models. A forward stepwise variable selection strategies on 52 physicochemical properties (descriptors) using 23 known drugs/compounds in the training set ([Tables S1](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)) identified four chemical descriptors, connectivity index (order 0, standard), dipole vector X (debye), molar refractivity and shape index (basic kappa, order 2), responsible for the anticancer activity against the SK-Br-3 cell line.

### QSAR model [equation 1](#fd3-dddt-11-1859){ref-type="disp-formula"}
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Spress is the standard predictive residual sum of squares; SDEP is the standard deviation of error of prediction.

The derived QSAR [equation 1](#fd3-dddt-11-1859){ref-type="disp-formula"} showed a significant relationship between log GI~50~ (dependent variable) and the chemical descriptors (independent variables). The value of the regression coefficient (*r*^2^=0.934) indicates the existence of \~93% correlation between the activity and the chemical descriptors in the training dataset, while the value of the cross-validation regression coefficient (rCV^2^=0.903) suggests \~90% prediction accuracy of this QSAR model ([Figure 1](#f1-dddt-11-1859){ref-type="fig"}). A Y-randomization of 100 trials with original descriptor producing an average value of 0.314 and 0.008 for *r*^2^ and rCV^2^, respectively, suggests the robustness and significant accuracy of the developed QSAR model ([Table S6](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)). Furthermore, test set predictivity of 0.868 supported the robustness and accuracy of the model. It is evident among the molecular descriptors that molar refractivity is positively correlated with activity, that is, if molar refractivity increases, the biological activity also increases. However, the connectivity index (order 0, standard), dipole vector X (Debye) and shape index (basic kappa, order 2) are inversely correlated showing an increase in the biological activity with the decrease in the magnitude of these descriptors and vice versa. Based on contributing descriptors, the predictivity of 29 withanolide analogs through a QSAR model indicated that 2,3-dihydrowithaferin A-3-beta-*O*-sulfate, withanolide 5, withanolide A, withaferin A, CID_10413139, CID_11294368, CID_53477765, CID_135887, CID_301751 and CID_3372729 showed significant anticancer in vitro activity compared to the reference drug camptothecin (CPT) against the SK-Br-3 cell line ([Table S7](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf) and [Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)).

QSAR model for antiproliferative activity against MCF7/BUS
----------------------------------------------------------

The QSAR model for antiproliferative activity against the MCF7/BUS cell line was developed with a training set of 24 drugs/compounds. A total of 52 chemical descriptors were considered during model development ([Table S2](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)), and forward stepwise variable search techniques resulted in four parametric models that included all atom count, dielectric energy (kcal/mole), total energy (hartree) and heat of formation (kcal/mole) correlating significantly against the MCF7/BUS cell line.

### QSAR model [equation 2](#fd4-dddt-11-1859){ref-type="disp-formula"}
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This QSAR equation shows the relationship between in vitro experimental activities (log GI~50~) as the dependent variable and the four chemical descriptors mentioned earlier as independent variables. The value of the regression coefficient (*r*^2^=0.91) shows the existence of \~91% correlation between the activities and the chemical descriptors of the training dataset compounds, while the value of cross-validation regression coefficient (rCV^2^=0.85) points to the 85% prediction accuracy of the QSAR model ([Figure 2](#f2-dddt-11-1859){ref-type="fig"}). A Y-randomization of 100 trials with the original descriptor producing an average value of 0.236 and 0.004 for *r*^2^ and rCV^2^, respectively, suggest the robustness of the developed QSAR model ([Table S6](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)). Furthermore, test set predictivity of 0.632 supported the robustness of the model. In the QSAR model, the molecular descriptors, namely, atom count (all atoms), dielectric energy (kcal/mole) and total energy (hartree), correlate positively with activity, that is, if any of these variables increase, the biological activity against the breast cancer also increases. Moreover, the heat of formation (kcal/mol) is negatively correlated with activity, showing that the biological activity decreases if the value of this descriptor increases. Analyzing the most active analogs, CID_73621 and CID_435144 possess higher anti-proliferative activity than the reference drugs 5-fluorouracil (5-FU) and CPT ([Table S8](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf) and [Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)).

Binding affinity and interactions with β-tubulin
------------------------------------------------

Molecular docking simulations were carried out to elucidate the likely binding affinity and binding interactions of withanolide analogs with anti-cancer target β-tubulin receptor protein. The predictions of the docking simulations are summarized in [Table 1](#t1-dddt-11-1859){ref-type="table"}. Withanolide analogs were found to bind to the same active site as found for X-ray crystal structure. The reference compounds 5-FU and CPT were predicted to have significant binding affinity to β-tubulin with total docking scores of 2.5304 and 4.1837, respectively, while withanolide active analogs CID_11294368 and CID_53477765 showed higher binding affinities with total docking scores of 6.4885 and 6.1862, respectively. The binding interactions of these withanolide analogs within the active site of β-tubulin receptor protein are shown in [Figure 3](#f3-dddt-11-1859){ref-type="fig"}. By contrast, 2,3-dihydrowithaferin A-3-beta-*O*-sulfate, withanolide 5, withanolide A, withaferin A, CID_73621, CID_435144, CID_10413139, CID_135887 and CID_301751 were predicted to have moderate binding affinities to β-tubulin with total docking scores of 5.6272, 5.958, 5.6691, 5.4153, 5.3516, 5.9275, 5.0615, 5.2200 and 5.2417, respectively. The withanolide analog CID_3372729 was predicted to have low binding affinity with β-tubulin showing a total docking score of 4.6965. The chemical nature of binding amino acid residues in β-tubulin that were predicted to interact with the various withanolide analogs was hydrophobic (eg, Ile-165, Pro-162, Met-166 and Val-257), polar acidic (eg, Asp-163 and Asp-199), polar basic (eg, Arg-158, Arg-164 and Arg-253), polar uncharged (eg, Thr-198) and polar amide (eg, Asn-197). Consequently, the interactions of all analogs with β-tubulin involved predominantly strong hydrophobic interactions, leading to high affinities and likely high anticancer activity. The active analogs also formed one to three H-bonds with β-tubulin, contributing to the strength of their interactions, which may lead to a high inhibitory activity of withanolide analogs with β-tubulin.

The most active compound, CID_301751, was predicted to have a significant binding affinity as evidenced by a total docking score of 5.2417 and form a hydrogen bond of length 1.8 Å to the polar acidic residue Asp-199. The amino acid residues binding within a radius of 3 Å with ligand were polar acidic residue Asp-199; polar uncharged residue Thr-198; nonpolar hydrophobic residues Ile-165, Met-166 and Val-257; polar amide Asn-197 and polar basic Arg-158. The presence of these strong hydrophobic and polar interactions explains the high affinity of this molecule and its anticancer activity ([Figure 4A](#f4-dddt-11-1859){ref-type="fig"}).

Docking of compound CID_3372729 against β-tubulin resulted in a predicted total docking score of 4.6965 and form a hydrogen bond of length 1.9 Å to the polar acidic residue Asp-199. The binding site amino acid residues within a radius of 3 Å with ligand were hydrophobic Ile-165, Pro-162, Met-166 and Val-257; polar uncharged Thr-198; polar basic Arg-158, Arg-164 and Arg-253; polar acidic Asp-163, Asp-199 and Glu-196 and polar amide Asn-197. The presence of these strong hydrophobic and polar interactions with β-tubulin explains the high affinity of this molecule and its anticancer activity ([Figure 4B](#f4-dddt-11-1859){ref-type="fig"}).

PK properties, DL and bioavailability
-------------------------------------

All the withanolide analogs were predicted for their ADME properties. The predicted properties have shown that all withanolide analogs satisfy the Lipinski's rule of five for oral bioavailability. The logP values were found to be in the range (logP\<5) for all the compounds; however, withanolide 3, CID_73621 and CID_435144 showed low membrane permeability due to somewhat high MW ([Table S9](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf)). The high value of their MWs in fact slightly violates one of Lipinski's rule of five, since it affects the drug excretion (elimination from the body). Moreover, previous studies have suggested that molecules with intermediate lipophilicity are more likely to arrive to the receptor site.[@b37-dddt-11-1859],[@b38-dddt-11-1859] Predictions related to MDCK cell, skin permeability (*K*~p~), Caco-2, CNS activity, metabolic reactions, log GI~50~ for HERG K+ channel blockage and human oral absorption in the gastrointestinal tract showed that these parameters for the active analogs fall within the standard ranges normally observed for drugs ([Table 2](#t2-dddt-11-1859){ref-type="table"}). On the other hand, BBB and intestinal absorption penetration were predicted by developing an ADME model using 2D descriptors polar surface area and ALogP98 that define 95% and 99% confidence ellipses. These ellipses define the regions where well-absorbed compounds are expected to be found. All withanolide analogs were predicted to possess \~95% confidence levels for human intestinal absorption and BBB penetration, except active compounds CID_73621, CID_135887 and CID_435144, which showed 99% confidence level for intestinal absorption and 95% confidence level for BBB penetration, indicating good intestinal absorption and BBB penetration ability. The values and plot of polar surface area and ALogP for the withanolide analogs are shown in [Table S10](https://www.dovepress.com/get_supplementary_file.php?f=130601.pdf) and [Figure 5](#f5-dddt-11-1859){ref-type="fig"}, respectively.

Toxicity risk assessment
------------------------

The US Food and Drug Administration standard toxicity risk predictor software Osiris Toxicity Properties Calculator locates fragments within the structure of a molecule that indicates a potential toxicity risk.[@b33-dddt-11-1859]--[@b35-dddt-11-1859] Toxicity risks parameters such as mutagenicity (MUT), tumorigenicity (TUMO), irritation (IRRI) and reproductive or developmental toxicity were computed for all the withanolide analogs. All compounds possess no risk of TUMO and developmental toxicity, with the exception of withanolide 2, which possesses high-risk developmental or reproductive toxicity. All active withanolide analogs were predicted to have high-risk MUT, except for compounds 2,3-dihydrowithaferin A-3-beta-*O*-sulfate, 12-deoxy-withastramonolide, withanolide 3, withanolide 5, withaferin A and CID_135887, which were predicted to have medium-risk toxicity. All active analogs were predicted to have high-risk skin IRRI, except for compounds 2,3-dihydrowithaferin A-3-beta-*O*-sulfate, 12-deoxy-withastramonolide, withanolide 1, withanolide 2, withanolide 3, withanolide 5, withaferin A and CID_135887, which showed medium-risk toxicity potential at high doses or long-term therapeutic use in human beings. The overall drug score (DS), which combines DL, hydrophilicity and toxicity risk parameters, was calculated for all compounds and was within acceptable limits ([Table 3](#t3-dddt-11-1859){ref-type="table"}). The overall DS for all the active compounds predicted to be moderate to good, compared to reference anticancer compounds 5-FU and CPT.

Conclusion
==========

There are numerous statistically proven examples, where combined approaches of QSAR and molecular docking-based prediction have been applied successfully in the field of drug design and discovery. The present work of QSAR and molecular docking-based prediction of withanolide analogs showed that 2,3-dihydrowithaferin A-3-beta-*O*-sulfate, withanolide 5, withanolide A, withaferin A, CID_10413139, CID_11294368, CID_53477765, CID_135887, CID_301751 and CID_3372729 against Sk-Br-3 and CID_73621, CID_435144, CID_301751 and CID_3372729 possess a significant anticancer activity against the MCF7/BUS. The QSAR results for SK-Br-3 suggested that connectivity index (order 0, standard), dipole vector X (Debye), molar refractivity, shape index (basic kappa, order 2), whereas for MCF7/BUS, atom count (all atoms), dielectric energy (kcal/mole), total energy (hartree) and heat of formation (kcal/mole) correlated well with the activity. In docking studies, active withanolide analogs showed high binding affinity against β-tubulin receptor protein. The withanolide analogs CID_301751 and CID_3372729 showed good predicted activity and binding affinity to β-tubulin receptor protein. The docking results showed that the major influencing factors of molecular interactions between withanolide analogs and β-tubulin were H-bonds and hydrophobic and electrostatic interactions. The in silico prediction of oral bioavailability (rule of five) and ADMET risk profiling were within their acceptable limit for active analogs. These compounds have rationalized the structural requirement and need further lead optimization for designing of novel β-tubulin inhibitors.
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![(**A**) Predicted interactions of CID_11294368 with anticancer target enzyme β-tubulin (PDB code 4IHJ) with a docking total score of 6.4885, revealing two H-bonds of length 2.1 and 1.6 Å, respectively, to the binding site pocket residues ASP-199 and PRO-162. (**B**) Predicted interactions of ID_53477765 with anticancer target enzyme β-tubulin (PDB code 4IHJ) with a docking total score of 6.1862, revealing a H-bond of length 1.9Å to the binding site pocket residue ASP-199.\
**Abbreviation:** PDB, Protein Data Bank.](dddt-11-1859Fig3){#f3-dddt-11-1859}

![(**A**) Predicted interactions of CID_301751 with anticancer target enzyme β-tubulin (PDB code 4IHJ) with a docking total score of 5.2417, revealing a H-bond of length 1.8 Å to the binding site pocket residue ASP-199. (**B**) Predicted interactions of CID_3372729 with the anticancer target enzyme β-tubulin (PDB code 4IHJ) with a docking total score of 4.6965, revealing a H-bond of length 1.9 Å to the binding site pocket residue ASP-199.\
**Abbreviation:** PDB, Protein Data Bank.](dddt-11-1859Fig4){#f4-dddt-11-1859}

![Plot of PSA versus ALogP for withanolide analogs showing the 95% and 99% confidence limit ellipses for BBB and intestinal absorption, respectively.\
**Abbreviations:** PSA, polar surface area; BBB, blood--brain barrier; ADMET, absorption, distribution, metabolism, excretion and toxicity.](dddt-11-1859Fig5){#f5-dddt-11-1859}

###### 

Comparison of binding affinities and interactions of standard anticancer drugs and active withanolide analogs for breast cancer receptor (PDB code 4IHJ)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound name                                Total score   Amino acids in active pocket within 4 Å                                                                      Interacting amino acids   H-bond length (Å)   No of H-bonds
  -------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------------ ------------------------- ------------------- ---------------
  2,3-Dihydrowithaferin A-3-beta-*O*-sulfate   5.6272        Arg-158, Pro-162, Asp-163, Met-166, Glu-196, Asn-197, Thr-198, Asp-199, Arg-253, Val-257                     Arg-158                   2.1                 1

  12-Deoxy-withastramonolide                   5.3729        Arg-158, Pro-162, Arg-164, Met-166, Glu-196, Asn-197, Thr-198, Asp-199, Arg-253, Val-257                     Arg-158                   2.1                 1

  Withanolide 1                                4.0823        Arg-158, Pro-162, Asp-163, Arg-164, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257                     Arg-158\                  2.1\                2
                                                                                                                                                                          Arg-164                   1.8                 

  Withanolide 2                                4.6426        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Asn-197                   2.0                 1

  Withanolide 3                                4.6662        Arg-158, Pro-162, Met-166, Glu-196, Asn-197, Thr-198, Asp-199, Arg-253, Val-257, His-266                     Pro-162\                  1.8\                3
                                                                                                                                                                          Arg-158\                  1.8\                
                                                                                                                                                                          Arg-253                   1.9                 

  Withanolide 4                                5.0296        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Arg-158                   2.0                 1

  Withanolide 5                                5.958         Arg-158, Pro-162, Met-166, Val-195, Glu-196, Asn-197, Thr-198, Asp-199, Arg-264, His-266                     Pro-162                   2.0                 1

  Withanolide A                                5.6691        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Asp-199                   1.7                 1

  Withaferin A                                 5.4153        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            --                        --                  --

  Withanolide D                                6.5523        Arg-158, Pro-162, Asp-163, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257                              Pro-162                   1.8                 1

  CID_73621                                    5.3516        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Asp-199\                  1.7\                3
                                                                                                                                                                          Arg-158\                  2.1\                
                                                                                                                                                                          Pro-162                   1.9                 

  CID_135887                                   6.2234        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Asp-199                   2.0\                2
                                                                                                                                                                                                    1.7                 

  CID_301754                                   4.4921        Arg-158, Val-195, Glu-196, Asn-197, Thr-198, Asp-199, Arg-253, Val-257, His-266                              Val-195\                  1.8\                2
                                                                                                                                                                          Arg-158                   1.9                 

  CID_435144                                   5.9275        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Asp-199                   2.1\                2
                                                                                                                                                                                                    1.9                 

  CID_3034071                                  5.8237        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Arg-253\                  2.1\                2
                                                                                                                                                                          Asp-199                   2.0                 

  CID_5315323                                  5.5121        Arg-158, Pro-162, Arg-164, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257                              --                        --                  --

  CID_10161347                                 4.8312        Arg-158, Pro-162, Asp-163, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257                     --                        --                  --

  CID_10413139                                 5.0615        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Asp-199, Val-257                              Asp-199                   1.8\                2
                                                                                                                                                                                                    2.0                 

  CID_11294368                                 6.4885        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Asp-199\                  2.1\                2
                                                                                                                                                                          Pro-162                   1.6                 

  CID_53477765                                 6.1862        Arg-158, Pro-162, Asp-163, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257                     Asp-199                   1.9                 1

  CID_161671                                   4.6248        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Glu-196, Asn-197, Thr-198, Asp-199, Arg-253, Val-257   Pro-162                   1.8                 1

  CID_135887                                   5.2200        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Asp-199                   2.1                 1

  CID_161671                                   6.3312        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Pro-162                   2.0                 1

  CID_301751                                   5.2417        Arg-158, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Val-257                                                Asp-199                   1.8                 1

  CID_3372729                                  4.6965        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Glu-196, Asn-197, Thr-198, Asp-199, Arg-253, Val-257   Asp-199                   1.9                 1

  CID_301751                                   5.6487        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Arg-253                   1.9                 1

  SID_50526634                                 4.576         Arg-158, Pro-162, Asp-163, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257                     --                        --                  --

  CID_11294368                                 5.6777        Arg-158, Pro-162, Asp-163, Arg-164, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257            Asp-199                   1.8                 --

  CID_161671                                   6.9272        Arg-158, Pro-162, Asp-163, Arg-164, Met-166, Asn-197, Thr-198, Asp-199, Arg-253, Val-257                     Pro-162\                  1.7\                --
                                                                                                                                                                          Arg-158                   2.1                 

  5-FU                                         2.5304        Ile-154, Arg-158, Tyr-161, Pro-162, Arg-164, Met-166, Asn-197                                                --                        --                  --

  CPT                                          4.1837        Ile-154, Ile-157, Arg-158, Tyr-161, Pro-162, Ile-165, Met-166, Asn-197, Thr-198, Asp-199, Arg-253            --                        --                  --
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** PDB, Protein Data Bank; 5-FU, 5-fluorouracil; CPT, camptothecin.

###### 

Predicted PK (ADME) properties of active withanolide analogs

  Compound name                                log *K*~hsa~ serum protein binding   No of primary metabolites   Predicted CNS activity       Log IC 50 for HERG K+ channel blockage   Apparent Caco-2 permeability (nm/sec)   Apparent MDCK permeability (nm/sec)   log *K*~p~ for skin permeability   Human oral absorption in GI tract (%) (±20%)   Qualitative model for human oral absorption
  -------------------------------------------- ------------------------------------ --------------------------- ---------------------------- ---------------------------------------- --------------------------------------- ------------------------------------- ---------------------------------- ---------------------------------------------- ---------------------------------------------
  2,3-Dihydrowithaferin A-3-beta-*O*-sulfate   0.336                                4                           −2                           −4.466                                   210.574                                 91.84                                 −4.012                             86.092                                         High
  12-Deoxy-withastramonolide                   0.51                                 5                           −2                           −4.56                                    263.97                                  117.252                               −3.825                             90.335                                         High
  Withanolide 1                                0.024                                5                           −2                           −4.227                                   305.469                                 137.297                               −3.864                             72.114                                         High
  Withanolide 2                                −0.023                               6                           −2                           −4.541                                   225.973                                 99.12                                 −4.116                             81.681                                         High
  Withanolide 3                                0.305                                6                           −2                           −4.462                                   141.57                                  59.793                                −4.417                             69.065                                         High
  Withanolide 4                                0.675                                5                           −1                           −4.37                                    864.965                                 422.915                               −3.007                             100                                            High
  Withanolide 5                                0.48                                 5                           −2                           −4.345                                   285.542                                 127.642                               −3.749                             90.626                                         High
  Withanolide A                                0.541                                6                           −1                           −4.447                                   610.905                                 290.411                               −3.209                             100                                            High
  Withaferin A                                 0.355                                4                           −2                           −4.491                                   241.508                                 106.506                               −3.896                             87.681                                         High
  Withanolide D                                1.314                                6                           0                            −4.743                                   2,770.276                               1,488.213                             −1.735                             100                                            Low
  CID_73621                                    0.114                                7                           −2                           −4.33                                    273.565                                 121.865                               −3.693                             70.883                                         Medium
  CID_135887                                   0.441                                10                          −2                           −4.327                                   167.469                                 71.699                                −4.263                             83.724                                         Low
  CID_301754                                   0.382                                5                           −2                           −4.417                                   451.939                                 209.668                               −3.472                             92.408                                         High
  CID_435144                                   0.417                                7                           −2                           −4.453                                   214.202                                 93.551                                −3.899                             73.332                                         Medium
  CID_3034071                                  0.616                                6                           −2                           −4.803                                   442.997                                 205.188                               −3.465                             95.507                                         High
  CID_5315323                                  0.566                                4                           −1                           −4.144                                   907.445                                 445.409                               −2.967                             100                                            High
  CID_10161347                                 0.571                                4                           −1                           −4.282                                   648.591                                 309.822                               −3.251                             100                                            High
  CID_10413139                                 0.419                                7                           −2                           −4.47                                    463.395                                 215.418                               −3.331                             93.191                                         High
  CID_11294368                                 0.543                                6                           −1                           −4.299                                   443.996                                 205.688                               −3.478                             94.259                                         High
  CID_53477765                                 0.415                                5                           −2                           −4.464                                   418.697                                 193.049                               −3.524                             92.181                                         High
  CID_161671                                   0.4                                  5                           −2                           −4.475                                   423.394                                 195.392                               −3.515                             92.07                                          High
  CID_135887                                   0.44                                 10                          −2                           −4.343                                   168.358                                 72.111                                −4.259                             83.774                                         Low
  CID_161671                                   0.921                                5                           −1                           −4.441                                   1,081.735                               538.556                               −2.839                             100                                            Low
  CID_301751                                   0.42                                 7                           −2                           −4.467                                   443.979                                 205.679                               −3.367                             92.789                                         High
  CID_3372729                                  0.386                                7                           −2                           −4.448                                   502.94                                  235.355                               −3.263                             93.487                                         High
  CID_301751                                   0.637                                6                           −1                           −4.332                                   682.735                                 327.488                               −3.104                             100                                            High
  SID_50526634                                 0.584                                4                           −1                           −4.167                                   819.929                                 399.165                               −3.066                             100                                            High
  CID_11294368                                 0.549                                6                           −1                           −4.409                                   521.407                                 244.71                                −3.343                             95.931                                         High
  CID_161671                                   0.399                                5                           −1                           −4.272                                   474.508                                 221.008                               −3.44                              93.029                                         High
  **5-FU**                                                                                                                                                                                                                                                                                                                                            
  CPT                                          −0.157                               3                           −1                           −5.144                                   527.805                                 247.957                               −2.931                             85.866                                         High
  Standard range                               −1.5/1.5                             1.0/8.0                     −2 (inactive), +2 (active)   Of concern \<−5                          \<25 poor, \>500 great                  \<25 poor, \>500 great                −8.0 to −1.0, *K*~p~ in cm/h       \<25% is poor                                  \>80% is high

**Abbreviations:** PK, pharmacokinetic; ADME, absorption, distribution, metabolism; GI, gastrointestinal; 5-FU, 5-fluorouracil; CPT, camptothecin.

###### 

Predicted toxicity risk parameters (MUT, TUMO, IRRI and REP) of active withanolide analogs

  Compound                                     Toxicity risk parameters   Drug-likeness parameters (Osiris)                                                       
  -------------------------------------------- -------------------------- ----------------------------------- ------------- ------------- ------- ------- ------- ------
  2,3-Dihydrowithaferin A-3-beta-*O*-sulfate   Medium risk                No risk                             Medium risk   No risk       −0.06   −3.25   1.93    0.36
  12-Deoxy-withastramonolide                   Medium risk                No risk                             Medium risk   No risk       2.55    −4.47   1.24    0.35
  Withanolide 1                                High risk                  No risk                             Medium risk   No risk       2.27    −4.43   −1.81   0.16
  Withanolide 2                                High risk                  High risk                           Medium risk   No risk       0.92    −3.9    −2.85   0.15
  Withanolide 3                                Medium risk                No risk                             Medium risk   No risk       2.49    −4.4    1.54    0.34
  Withanolide 4                                High risk                  No risk                             High risk     No risk       3.5     −4.98   −1.04   0.13
  Withanolide 5                                Medium risk                No risk                             Medium risk   No risk       2.55    −4.47   124     0.35
  Withanolide A                                High risk                  No risk                             High risk     No risk       2.3     −4.53   −0.63   0.15
  Withaferin A                                 Medium risk                No risk                             Medium risk   No risk       2.55    −4.47   1.69    0.37
  Withanolide D                                High risk                  No risk                             High risk     No risk       2.13    −4.48   −0.43   0.16
  CID_73621                                    High risk                  No risk                             High risk     No risk       0.93    −3.63   0.97    0.21
  CID_135887                                   Medium risk                No risk                             High risk     No risk       2.18    −3.96   1.31    0.21
  CID_301754                                   High risk                  No risk                             High risk     No risk       2.3     −4.53   0.14    0.17
  CID_435144                                   High risk                  No risk                             High risk     No risk       1.6     −3.76   0.83    0.2
  CID_3034071                                  High risk                  No risk                             High risk     No risk       2.78    −4.58   −0.19   0.15
  CID_5315323                                  High risk                  No risk                             High risk     No risk       3.5     −4.98   −0.6    0.14
  CID_10161347                                 High risk                  No risk                             High risk     No risk       3.5     −4.98   −0.6    0.14
  CID_10413139                                 High risk                  No risk                             High risk     No risk       2.44    −4.48   −0.41   0.16
  CID_11294368                                 High risk                  No risk                             High risk     No risk       2.3     −4.53   −0.63   0.15
  CID_53477765                                 High risk                  No risk                             High risk     No risk       2.02    −4.35   0.06    0.18
  CID_161671                                   High risk                  No risk                             High risk     No risk       2.3     −4.53   0.14    0.17
  CID_135887                                   High risk                  No risk                             High risk     No risk       2.71    −4.3    0.7     0.19
  CID_161671                                   High risk                  No risk                             High risk     No risk       3.6     −5.26   1.65    0.17
  CID_301751                                   High risk                  No risk                             High risk     No risk       2.44    −4.58   −0.49   0.15
  CID_3372729                                  High risk                  No risk                             High risk     No risk       1.76    −4.03   −0.41   0.16
  CID_301751                                   High risk                  No risk                             High risk     No risk       2.44    −4.49   0.55    0.15
  SID_50526634                                 High risk                  No risk                             High risk     No risk       3.5     −4.96   −0.6    0.14
  CID_11294368                                 High risk                  No risk                             High risk     No risk       2.98    −4.74   −0.44   0.14
  CID_161671                                   High risk                  No risk                             High risk     No risk       2.3     −4.53   0.14    0.17
  CPT                                          High risk                  High risk                           No risk       Medium risk   1.48    −2.74   5.35    0.25

**Abbreviations:** MUT, mutagenicity; TUMO, tumorigenicity; IRRI, irritation; REP, reproduction; CLP, CLogP; S, solubility; DL, drug-likeness; DS, drug score.
